The Effect of Semaglutide on Antipsychotic-Induced Weight Gain and Other Metabolic Parameters, among a Cohort of Inpatients
Open accessThe DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index; 11 of the 12 sources its claims cite were checked for support.
Abstract
BACKGROUND AND HYPOTHESIS: Antipsychotic use in severe mental illnesses (SMI) is associated with metabolic dysregulation, including antipsychotic-induced weight gain (AIWG), type 2 diabetes (T2D), and dyslipidemia. In the case of non-response to metformin which is currently recommended for AIWG mitigation, no clear alternatives exist. Semaglutide, a weekly injectable glucagon like peptide-1 receptor agonist, represents a promising option. However, effectiveness and safety data in SMI are lacking. With initiation of semaglutide, we hypothesized weight loss, improvements in metabolic indices, and good tolerability. STUDY DESIGN: A retrospective chart review was conducted for inpatients receiving antipsychotics, initiated on once-weekly subcutaneous semaglutide between January 4, 2018 and March 31, 2024 at the Centre for Addiction and Mental Health in Toronto, Canada, that analyzed weight loss, metabolic parameters, and side effects. STUDY RESULTS: 47 individuals with SMI were included: 59.6% males, mean age of 43 ± 13.2 years, 83% had dysglycemia, and 66% had T2D at baseline. The maximum dose of semaglutide in this cohort was 2 mg/week. There was a mean weight loss of 3.15 ± 0.77 kg (n = 47), 7.27 ± 0.97 kg (n = 24), 9.33 ± 1.16 kg (n = 15), and 12.25 ± 1.32 kg (n = 11) at 3, 6, 9, and 12 months, respectively (P < .001). Individuals without T2D experienced greater weight loss versus those with T2D (P = .022). Additionally, significant decreases were noted in body mass index and HbA1c (P < .001), alongside improvements in lipid parameters; most common side effects were gastrointestinal in nature but did not result in semaglutide discontinuation. CONCLUSION: This retrospective chart review of inpatients with SMI supports efficacy and safety of semaglutide up to a year of follow-up, warranting future adequately powered randomized controlled trials.
Overview
CoChat Summary
TL;DR
In this retrospective inpatient chart review of 47 people with severe mental illness on antipsychotics, semaglutide was associated with significant weight loss and improvements in several metabolic measures over up to 12 months. The authors report generally good tolerability, with gastrointestinal side effects common but no discontinuations due to adverse effects.
Key findings
- In 47 individuals, mean weight loss was 3.15 ± 0.77 kg at 3 months, 7.27 ± 0.97 kg at 6 months, 9.33 ± 1.16 kg at 9 months, and 12.25 ± 1.32 kg at 12 months; all were P < .001.
- The paper reports an adjusted 10.7% weight loss over 12 months.
- BMI and HbA1c both declined significantly over time; HbA1c fell by about 1.1% to 1.2% at 3 to 12 months (P < .001 at each timepoint), and BMI fell by 1.18 ± 0.29 to 4.33 ± 0.50 kg/m² over 3 to 12 months.
- Semaglutide was associated with significant reductions in total cholesterol (P = .004), LDL (P = .008), and triglycerides (P < .001), while HDL was not significant (P = .28).
- People without T2D lost more weight than those with T2D (P = .022); weight loss in the semaglutide-only vs semaglutide-plus-metformin comparison was not significant (P = .50).
- The most common side effects were gastrointestinal; at 3 months, 27.7% (13/47) reported newly noted nausea/diarrhea/vomiting and 21.3% (10/47) reported ongoing constipation, and no discontinuations due to adverse effects were reported.
Methods
- Retrospective chart review at the Centre for Addiction and Mental Health (Toronto, Canada) of inpatients with severe mental illness receiving antipsychotics and started on once-weekly subcutaneous semaglutide between January 4, 2018 and March 31, 2024.
- Sample: 47 individuals with SMI; baseline data included demographics, antipsychotic and concomitant psychotropic medications, anthropometrics, HbA1c, and lipid parameters. Follow-up was assessed at baseline, 3, 6, 9, and 12 months when available.
- Main analysis: linear mixed models for weight and secondary outcomes, adjusted for age, sex, and baseline values; subgroup analyses examined T2D vs no T2D, semaglutide alone vs with metformin, and with vs without clozapine.
Limitations
- The authors state that not all anthropometric and metabolic variables were collected in a standardized manner, leading to missing data and limiting analyses.
- They also note loss to follow-up after 3 months, especially by 12 months, largely because patients were discharged to the community, which reduced statistical power.
- The paper says it could not capture all obesity-related comorbidities that semaglutide might affect, and that patients who were offered semaglutide but declined were unknown, limiting generalizability.
- Evident from the text: the study is a retrospective, uncontrolled chart review with a small sample and uneven follow-up counts over time, so causal inference is limited.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
4 Valid · 3 Not valid · 1 Not checked · 31 Own results and interpretations
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“However, these studies excluded individuals with mental health diagnoses.”
§ The Effect of Semaglutide on Antipsychotic-Induced Weight Gain and Other Metabolic Parameters, among a Cohort of Inpatients > Introduction
What the sources say
- Could not verifycites [30] Liu, 2025, Safety and effects of anti-obesity medications on weight loss, cardiometabolic, and psychological outcomes in people living with overweight or obesity: a systematic review and meta-analysis, eClinicalMedicine. sourceExperimental — accuracy not yet measured
The Methods (Search strategy and selection criteria; page unavailable) give the review’s criteria for including trials, not the STEP trials’ participant-exclusion criteria. The Results report participants with psychiatric disorder-related overweight or obesity in the pooled studies, but do not identify whether STEP or the related trials excluded people with mental health diagnoses. Searches for STEP and psychiatric exclusion found no passage settling that specific claim. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The most common side effects were gastrointestinal.”
§ The Effect of Semaglutide on Antipsychotic-Induced Weight Gain and Other Metabolic Parameters, among a Cohort of Inpatients > Results > Exploratory Outcomes
plainn = 47- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Figure 1 details the mean adjusted change in weight over the 12-month period, displaying an adjusted 10.7% weight loss.”
§ The Effect of Semaglutide on Antipsychotic-Induced Weight Gain and Other Metabolic Parameters, among a Cohort of Inpatients > Results > Primary Outcome
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“While an interaction effect of semaglutide dose and time was not significant in our sample (F(4, 88.37 = 1.12; P = .35))”
§ The Effect of Semaglutide on Antipsychotic-Induced Weight Gain and Other Metabolic Parameters, among a Cohort of Inpatients > Results > Primary Outcome
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“no significance was found (F(4, 89.13) = 0.85; P = .50) between the two groups.”
§ The Effect of Semaglutide on Antipsychotic-Induced Weight Gain and Other Metabolic Parameters, among a Cohort of Inpatients > Results > Primary Outcome
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
9 more claims
Create a free account to see all 39 claims and every source verdict.
- Probably not a substantial claim. 7
- It may state two separate claims as one. 18
- Borderline: one of the tests for a substantial claim is unclear. 1
- The quote only partly states this claim. 1
Statistics recomputed
Every reported test result, recomputed from its test statistic and degrees of freedom. A result shows as not adding up only once an independent check has confirmed it.
- ConsistentF(4, 89.13) = 3.03reported p = .022 · recomputed p = .022
“F (4, 89.13) = 3.03, p = .022”
- ConsistentF(4, 89.13) = 0.85reported p = .5 · recomputed p = .497
“F(4, 89.13) = 0.85, p = .50”
- ConsistentF(4, 89.13) = 0.25reported p = .91 · recomputed p = .909
“F(4, 89.13) = 0.25, p = .91”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Self-check results appear here once an independent check has confirmed them.
Citations
Cites
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205 · cited 4×
“36 Similarly, the STEP 2 study which included individuals with T2D reported a mean weight decrease of 9.6% from baseline.”
InfluentialDE HERT, M., CORRELL, C. U., BOBES, J., CETKOVICH‐BAKMAS, M., COHEN, D., ASAI, I., DETRAUX, J., GAUTAM, S., MÖLLER, H., NDETEI, D. M., et al. (2011) · World Psychiatry · doi:10.1002/j.2051-5545.2011.tb00014.x · Cited by 2,488 · cited 1×
“7 – 9 Obesity remains an important cardiometabolic risk factor in SMI not only due to lifestyle factors ranging from an unhealthy diet and behaviors to a lack of physical activity, 10 but also owing to metabolic dysregulation associated with antipsychotic treatments.”
Saha, S., Chant, D., & McGrath, J. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.10.1123 · Cited by 2,065 · cited 1×
“36 While we saw consistent changes at 3, 6, 9, and 12 months in measures of BMI, HbA1c, and triglyceride levels, LDL and total cholesterol levels only became significant after the 3-month timepoint.”
Obesity in adults: a clinical practice guideline
Wharton, S., Lau, D. C. W., Vallis, M., Sharma, A. M., Biertho, L., Campbell-Scherer, D., Adamo, K., Alberga, A., Bell, R., Boulé, N., et al. (2020) · Canadian Medical Association Journal · doi:10.1503/cmaj.191707 · Cited by 1,506
Self-citationDavies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T. A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00213-0 · Cited by 1,419 · cited 3×
“29 , 37 It should be highlighted that greater HbA1c improvements have been observed with semaglutide, compared to earlier generation GLP-1RAs.”
InfluentialSchizophrenia and increased risks of cardiovascular disease
Hennekens, C. H., Hennekens, A. R., Hollar, D., & Casey, D. E. (2005) · American Heart Journal · doi:10.1016/j.ahj.2005.02.007 · Cited by 1,070 · cited 1×
“2 , 3 Moreover, patients with SMI die on average 15 to 20 years earlier from cardiovascular disease 4 and the standardiz ed mortality ratios of people with SMI including schizophrenia spectrum disorders are 2.5 times higher than the general population.”
InfluentialTrends in the Leading Causes of Death in the United States, 1970-2002
Jemal, A. (2005) · JAMA · doi:10.1001/jama.294.10.1255 · Cited by 987
Lehman, A. F., Steinwachs, D. M., & The Co-Investigators of the PORT Project (1998) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a033302 · Cited by 910
Prevalence and Correlates of Diabetes in National Schizophrenia Samples
Dixon, L., Weiden, P., Delahanty, J., Goldberg, R., Postrado, L., Lucksted, A., & Lehman, A. (2000) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a033504 · Cited by 569
Mitchell, A. J., Delaffon, V., Vancampfort, D., Correll, C. U., & De Hert, M. (2012) · Psychological Medicine · doi:10.1017/s003329171100105x · Cited by 332 · cited 1×
“27 The Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes (SUSTAIN) trials 1 to 7 showed a mean body weight reduction ranging from 3.5 to 4.6 kg with semaglutide doses ranging from 0.5 to 1 mg weekly.”
Influential
Research works printed but not linked: 2
- Collins, 2024, StatPearls
- WHO Collaborating Centre for Drug Statistics Methodology, ATCDDD—ATC/DDD Index 2025
Cited by
Zhuang, J., Zhou, Y. K., Yu, G., Cheng, H., Chen, X., & Qian, R. (2026) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2026.1845876
“…– documented metabolic and neurological side effects — including weight gain, type 2 diabetes, dyslipidemia, tachycardia, and parkinsonian symptoms (153, 154) — the broad – category AE analysis revealed no signi fi cant differences among interventions (all 95% CrIs included 1), and combination…”
Metadata
- Authors
- De, R., Amin Alfatwa, Y., Kanagasundaram, P., Saragosa, J. E., Chan, J., Remington, G., Retnakaran, R., Sanches, M., Sockalingam, S., Agarwal, S. M., & Hahn, M. K.
- Affiliations
- Centre for Addiction and Mental Health (CA)
- Complex Care and Recovery, Centre for Addiction and Mental Health (CAMH) , Toronto , ON, M6J 1H3,
- Mount Sinai Hospital (CA)
- University of Copenhagen (DK)
- Corresponding author
- Agarwal, Sri Mahavir
- Hahn, Margaret K
- ORCID
- Venue
- Schizophrenia Bulletin
- Publisher
- Oxford University Press (OUP)
- Published
- 2026-04-10
- Volume
- 52
- Issue
- 3
- ISSN
- 0586-7614 (ISSN-L)
- 1745-1701
- PMC
- PMC13267902
- OpenAlex
- W7164814392
- Cited by
- 1
- References
- 44
- Citations by year
- 2026: 1
- FWCI
- 0.53
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Schizophrenia Bulletin (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, cc-by-nc-nd)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- semaglutide, antipsychotic-induced weight gain
- MeSH terms
- Semaglutide, Adult, Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Female, Humans, Hypoglycemic Agents, Male, Middle Aged, Retrospective Studies, Schizophrenia, Antipsychotic Agents, Weight Gain, Outcome Assessment, Health Care, Dyslipidemias
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Effect of Semaglutide on Antipsychotic-Induced Weight Gain and Other Metabolic Parameters, among a Cohort of Inpatients. https://app.cochat.ai/papers/10.1093/schbul/sbaf236
- The paper
- De, R., Amin Alfatwa, Y., Kanagasundaram, P., Saragosa, J. E., Chan, J., Remington, G., Retnakaran, R., Sanches, M., Sockalingam, S., Agarwal, S. M., & Hahn, M. K. (2026). The Effect of Semaglutide on Antipsychotic-Induced Weight Gain and Other Metabolic Parameters, among a Cohort of Inpatients. Schizophrenia Bulletin. https://doi.org/10.1093/schbul/sbaf236
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.